Paratek Inc. IPO Advisory

IPO Research - IPO Boutique



Home

Subscriptions



Company
Symbol
Price
Shares
Trade Date
Paratek Pharmaceuticals, Inc.PRTK
[ Nasdaq ]
0.00TBD
Underwriter(s):
UBS Investment Bank, Leerink Swann
Co-Manager(s):
Employees:
32
Founded:
1996
Address:
75 Kneeland Street, Boston, MA 02111
Phone:
617-275-0040
Paratek Inc. Web Site:
http://www.paratekpharm.com


For IPO Boutique's "scale of 1 to 5" BUY rating on Paratek Pharmaceuticals, Inc., and our comprehensive analysis, click the "Buy Market Research" link above.




About Paratek Inc. (adapted from Paratek Inc. prospectus):
Paratek is a pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Their lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians.

This description is adapted from Paratek Inc. prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..


IPO Boutique aggregates information on public companies and private companies, such as Paratek Inc. "PRTK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.




Need a recommendation?
Visit our Testimonials page and see over 200 investors singing our praises.



Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2014 IPO Boutique. All Rights Reserved